1Parkin DM, Bray F, Fer|ay J, et al. Globle cancer statistics, 2002 [J]. CA Cancer J Clin,2005,55( 1 ) :74 - 108.
2Llovet JM, Bruix J. Molecular targeted therapies in hepatocellu- lar carcinoma[ J]. Hepatology, 2008, 48 (4) : 1312 - 1327.
3Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity andtargets theRAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor pro- gression and angiogenesis[ J]. Cancer Res, 2004,64(19) :7099 -7109.
4Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatoeellular carcinoma[J]. N Engl J Med, 2008,359(4) :378 - 390.
5Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sor- afenib in patients in the Asia-Pacific region with advancedhepato- cellular carcinoma : a phase m randomised, double-blind, placebo- controlled trial[ J ]. Lancet Oncol, 2009,10 ( 1 ) :25 - 34.
6Welker MW, Lubomierski N, Gog C, et al. Efficacy and safety oforafenib in advanced hepatocellular carcinoma under daily prac- tice conditions[ J]. J Chemother,2010,22 ( 3 ) :205 - 211.
7Lencioni R, Kudo M, Ye SL,et al. First interim analysis of the GIDEON ( Global Investigation of therapeutic decisions in hepato- cellular carcinoma and of its treatment with sorafenib) non-inter- ventional study [ J ]. Int J Clin Pract,2012,66 ( 7 ) : 675 - 683.
8Chung YH, Han G, Yoon JH,et al. Interim analysis of START: study in Asia of the combination of TACE ( transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial[ J]. Int J Cancer,2013,132 (10) :2448 - 2458.
